Breast Cancer Drug

Source: news.yahoo.com --- 40 days ago
HealthDay - TUESDAY, Sept. 2 (HealthDay News) -- Contrary to previous study results, the Cancer prevention Drug anastrozole does not appear to cause impairment of cognitive performance, a new study found. ...

Source: www.moreover.com --- 41 days ago
TUESDAY, Sept. 2 (HealthDay News) -- Contrary to previous study results, the Cancer prevention Drug anastrozole does not appear to cause impairment of cognitive performance, a new study found. ...

Source: www.moreover.com --- 23 days ago
Natco Pharma, an Indian pharmaceutical company, has launched Albupax, its first nanotechnology Drug. Albupax is the first generic version of the international brand Abraxane of Abraxis BioSciences, USA, with sales of approximately US$375 million. ...

Source: www.moreover.com --- 20 days ago
Report from Asian News International brought to you by HT Syndication. Washington, Sept. ...

Source: www.ncbi.nlm.nih.gov --- 23 days ago
Related Articles [Marked Efficacy of S-1 against Hepatic Metastasis of Multiple Drug-Resistant Breast Cancer-A Report of 2 Cases.] Gan To Kagaku Ryoho. 2008 Sep;35(9):1603-6 Authors: Shiba E, Yamamoto H, Takahara S, Tokushima H S-1 was found to be highly effective against metastatic hepatic lesions from multiple Drug-resistant Breast cancers, in 2 patients. The details of these cases are presented below. Case 1, a 59-year-old woman, was HER2-positive. For chemotherapy following a recurrence, trastuzumab+weekly paclitaxel and trastuzumab+vinorelbine regimens were attempted, but the hepatic metastasis worsened. On the other hand, a trastuzumab+S-1 regimen resulted in a notable reduction in the metastatic foci of the liver approximately one month after the initiation of the therapy. This effect was sustained for 5 months thereafter. Case 2 involved a 67-year-old woman with HER2-negative Breast Cancer. Following a recurrence, chemotherapeutic agents, such as taxane and vinorelbine, were applied, which all resulted in PD. Treatment with S-1 alone reduced the size of the hepatic metastatic lesion, as seen in case 1. Currently(14 months after the initial treatment with S-1), therapeutic efficacy has been maintained. Adverse effects were minimal and QOL was not compromised in either case. We speculate that S-1 is not only effective as a therapeutic agent but is also useful in view of safety and QOL. PMID: 18799921 [PubMed - in process] ...

Source: www.usatoday.com --- 1 day ago
Experts say the Drug that has kept Barbara Bradfield healthy for so long, Herceptin, has changed the nature of Breast Cancer ... ...

Source: www.dailymail.co.uk --- 27 days ago
A cheap bone-strengthening Drug could help Breast Cancer victims cut their chances of getting the disease again by a third, scientists say. ...

Source: www.medscape.com --- 16 days ago
Acupuncture was as effective as venlafaxine in reducing vasomotor symptoms in Breast Cancer patients who are taking tamoxifen or anastrozole. Medscape Medical News ...

Source: www.associatedcontent.com --- 28 days ago
News story about Breast Cancer ...

Source: www.katu.com --- 2 days ago
“Acupuncture has been proven to help in other settings,” says Nathalie Johnson, M.D., principal investigator of the clinical trials.  “If it makes a difference here, we can improve outcomes after surgery for so many other future Breast Cancer survivors.” ...

Source: info.cancerresearchuk.org --- 5 days ago
A 'one-stop' Drug treatment could one day be developed to prevent Breast Cancer, one of Britain's leading researchers has said. ...

Source: www.icenews.is --- 6 days ago
Actavis, a generic drugs manufacturer based in Iceland, has received approval from the US Food & Drug Administration to market the generic Breast Cancer Drug, Epirubicin Hydrochloride Injection, in the United States. The Drug will be Actavis’ second oncology Drug introduced to the US this year. Epirubicin Hydrochloride Injection, the generic to Pfizer’s Ellence, is prescribed [...] ...

Source: www.pnwlocalnews.com --- 12 days ago
...

Source: www.healingwell.com --- 40 days ago
Researchers say finding is 'good news' for postmenopausal women taking anastrozole ...

Source: www.scienceblog.com --- 21 days ago
Acupuncture is as effective and longer-lasting in managing the common debilitating side effects of hot flashes, night sweats, and excessive sweating (vasomotor symptoms) associated with Breast Cancer treatment and has no treatment side effects compared to conventional Drug therapy. read more ...

Source: www.topix.com --- 38 days ago
Breast Cancer patients have been offered new hope after scientists discovered a kidney Cancer Drug could help boost other treatments when the effects start to wear off. ...

Source: www.topix.com --- 33 days ago
New Brunswick-based Johnson & Johnson said it asked the U.S. Food and Drug Administration for approval to market its Drug Doxil in combination with Sanofi-Aventis SA's Taxotere for treatment of women with ... ...

Source: www.nanovip.com --- 23 days ago
Short description NATCO makes a debut in nano-technology, launches Albupax Article body Hyderabad based NATCO Pharma Limited has launched its first nano-technology Drug – Albupax. Albupax is the first generic version of the international brand – Abraxane - (2007 sales approximately US $ 375 Million) of Abraxis Bio-sciences, USA. Albupax, which is the brand name of NATCO, consists of Paclitaxel in an Albumin bound nano-particle form. Albupax is used in the treatment of Breast Cancer. The incidence of Breast Cancer is on the rise in India, and currently over a lakh new patients are added every year. By 2015, the number of new cases are likely to go upto 2 lakhs every year. Albupax replaces the conventional Paclitaxel and has the advantage of having least side effects. In the conventional Paclitaxel, the solvent polyethylated castor oil is used, which causes severe side effects such as neutropenia, hyper-sensitivity reactions and neuropathy. Albupax does not contain this solvent, and hence can be given in optimum doses for enhanced efficacy. Albupax has been indigenously developed by NATCO in India and is the first albumin bound Paclitaxel in nano-particle to be developed in India. Each 100 mg vial of Albupax has been affordably priced at Rs. 11,500. The estimated Indian market for this product is in the region of Rs. 150 Crores and NATCO expects Albupax to garner a reasonable share of this market. NATCO believes that Albupax has the pot ...

Source: clubmailform.seo-blog.org --- 6 days ago
As part of all stock deal, Citi will acquire deposits, loans from nation. By MICHAEL SLACKMAN and MONA EL NAGGAR CAIRO Commando forces from Egypt and Sudan on Monday freed hostages grabbed by desert gunmen during a tourist expedition in a remote corner of Egypt days ago, government officials announced. S strongest debate [...] ...